Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Sarcoma 1

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Breast Neoplasms 2Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 21Carboplatin 19Paclitaxel 14Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 9Biopsy 9Capecitabine 6sacituzumab govitecan 5Taxes 5Nivolumab 5Doxorubicin 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5olaparib 4Gemcitabine 4fludarabine 3eribulin 3durvalumab 3Fulvestrant 3Bevacizumab 3veliparib 2tucatinib 2poly ICLC 2atezolizumab 2aldesleukin 2abemaciclib 2Radiotherapy 2Radiation 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × veliparib × 30 days × Clear all
NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
44 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡